ECSP17005649A - Anticuerpos anti-tau humanizados - Google Patents
Anticuerpos anti-tau humanizadosInfo
- Publication number
- ECSP17005649A ECSP17005649A ECIEPI20175649A ECPI201705649A ECSP17005649A EC SP17005649 A ECSP17005649 A EC SP17005649A EC IEPI20175649 A ECIEPI20175649 A EC IEPI20175649A EC PI201705649 A ECPI201705649 A EC PI201705649A EC SP17005649 A ECSP17005649 A EC SP17005649A
- Authority
- EC
- Ecuador
- Prior art keywords
- tauopathy
- antibodies
- antigen
- chain variable
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Optics & Photonics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018436P | 2014-06-27 | 2014-06-27 | |
| US201462080903P | 2014-11-17 | 2014-11-17 | |
| US201562170036P | 2015-06-02 | 2015-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17005649A true ECSP17005649A (es) | 2018-04-30 |
Family
ID=54938957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI20175649A ECSP17005649A (es) | 2014-06-27 | 2017-01-27 | Anticuerpos anti-tau humanizados |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9957317B2 (https=) |
| EP (1) | EP3182987B1 (https=) |
| JP (3) | JP6626892B2 (https=) |
| KR (1) | KR102431596B1 (https=) |
| CN (1) | CN106659759B (https=) |
| AU (2) | AU2015279643B2 (https=) |
| BR (1) | BR112016030686A2 (https=) |
| CA (2) | CA3094638A1 (https=) |
| CL (1) | CL2016003346A1 (https=) |
| CR (1) | CR20170026A (https=) |
| DO (1) | DOP2016000335A (https=) |
| EC (1) | ECSP17005649A (https=) |
| ES (1) | ES2959528T3 (https=) |
| IL (3) | IL249734B (https=) |
| MA (1) | MA40229A (https=) |
| MX (2) | MX384790B (https=) |
| MY (1) | MY184540A (https=) |
| NZ (1) | NZ727919A (https=) |
| PE (1) | PE20170665A1 (https=) |
| PH (2) | PH12016502608A1 (https=) |
| RU (1) | RU2743152C2 (https=) |
| SG (2) | SG11201610862VA (https=) |
| TW (3) | TWI734975B (https=) |
| UA (1) | UA122771C2 (https=) |
| UY (1) | UY36194A (https=) |
| WO (1) | WO2015200806A2 (https=) |
| ZA (1) | ZA201608875B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201708959WA (en) | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US20200030445A1 (en) * | 2015-06-12 | 2020-01-30 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
| SI3445785T1 (sl) | 2016-04-18 | 2022-11-30 | Faron Pharmaceuticals Oy, | Humanizirana protitelesa proti CLEVER-1 in njihova uporaba |
| PT3452507T (pt) * | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| CA3030754C (en) * | 2016-07-20 | 2022-04-26 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| CN116492457A (zh) * | 2016-09-10 | 2023-07-28 | 耶达研究与开发有限公司 | 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤 |
| AU2017335634A1 (en) | 2016-09-27 | 2019-03-14 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| MX2019006330A (es) | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| UA128383C2 (uk) | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| EP4714966A2 (en) | 2017-09-26 | 2026-03-25 | Cero Therapeutics Holdings, Inc. | Chimeric engulfment receptor molecules and methods of use |
| EP3691639B1 (en) | 2017-10-02 | 2023-11-15 | Merck Sharp & Dohme LLC | Chromane monobactam compounds for the treatment of bacterial infections |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| WO2019180261A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| WO2019191332A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| MX2020010241A (es) | 2018-03-28 | 2020-10-16 | Cero Therapeutics Inc | Composiciones de inmunoterapia celular y usos de las mismas. |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| MX2021001268A (es) | 2018-08-01 | 2021-09-08 | Imcheck Therapeutics Sas | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2020201828A1 (en) * | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| EP4001305A4 (en) * | 2019-07-15 | 2022-10-12 | Adel Inc. | ANTI-TAU ANTIBODIES AND ITS USE |
| JP7181438B2 (ja) | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| JP7713956B2 (ja) * | 2020-04-15 | 2025-07-28 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| US20230235034A1 (en) * | 2020-05-26 | 2023-07-27 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological tau, and methods using same |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| JP2024534151A (ja) | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| US20250134952A1 (en) | 2021-09-20 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN118871989A (zh) | 2022-03-14 | 2024-10-29 | 基因泰克公司 | 基于语音分析来预测神经退行性疾病 |
| JP2025525371A (ja) | 2022-06-21 | 2025-08-05 | ジェネンテック， インコーポレイテッド | 音声分析に基づくアルツハイマー病（ａｄ）の長期的進行の検出 |
| CN115724970B (zh) * | 2022-07-27 | 2023-10-20 | 生工生物工程（上海）股份有限公司 | 一种特异性结合e-cad多肽的结合蛋白及其应用 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116375857A (zh) * | 2023-03-30 | 2023-07-04 | 天津鸿宇泰生物科技有限公司 | 一种用于检测Tau蛋白的单链抗体及其制备方法和应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN119331085B (zh) * | 2024-10-16 | 2025-03-14 | 中国科学院合肥物质科学研究院 | 沙贝冠状病毒广谱中和抗体及其应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01163661A (ja) | 1987-10-02 | 1989-06-27 | E I Du Pont De Nemours & Co | ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ |
| EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
| US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
| DE69220503T2 (de) | 1991-10-25 | 1998-02-05 | Innogenetics Nv | Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau. |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| DK0618968T3 (da) | 1991-12-06 | 2000-04-10 | Max Planck Gesellschaft | Midler til diagnostisering og behandling af Alzheimer's sygdom |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
| WO1996004309A1 (en) | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
| BR9913112A (pt) | 1998-09-08 | 2001-05-08 | Innogenetics Nv | Tau como um marcador para dano inicial de cns |
| US6972125B2 (en) * | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
| JP4582874B2 (ja) | 2000-07-13 | 2010-11-17 | 富士通株式会社 | 偏波モード分散補償方法および偏波モード分散補償装置 |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP3960855A1 (en) | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| SG187991A1 (en) | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| US20060167227A1 (en) | 2002-07-12 | 2006-07-27 | Axon Neuroscience Forschungs-Und Entwicklungs Gmbh | Truncated tau proteins |
| JP4393382B2 (ja) | 2002-08-14 | 2010-01-06 | 三菱化学株式会社 | 中枢性タウ蛋白質特異的抗体 |
| FI20030652A0 (fi) | 2003-04-30 | 2003-04-30 | Susann Eriksson | Parannettu immunomääritys |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| DK1716233T3 (da) * | 2004-01-30 | 2009-10-26 | Maxygen Holdings Ltd | Reguleret stopkodongennemlæsning |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| CA2598321A1 (en) | 2005-02-19 | 2006-08-24 | Peoplebio, Inc. | Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides |
| WO2007019273A2 (en) | 2005-08-04 | 2007-02-15 | Albert Einstein College Of Medicine Of Yeshiva University | Phosphorylation of tau by abl |
| ES2321996B1 (es) | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias. |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| MX2009000709A (es) * | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| MX2010011209A (es) | 2008-04-24 | 2010-11-12 | Squibb Bristol Myers Co | Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer. |
| CN101307108B (zh) | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| WO2010096751A1 (en) | 2009-02-23 | 2010-08-26 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| WO2010129674A2 (en) | 2009-05-05 | 2010-11-11 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| WO2010146792A1 (ja) | 2009-06-17 | 2010-12-23 | 株式会社フジクラ | マルチクラッド光ファイバ、光ファイバモジュール、ファイバレーザ及びファイバアンプ |
| JP2013500326A (ja) | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
| AU2010286501B2 (en) | 2009-08-28 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Antibodies that bind Tau oligomers |
| CN102549438B (zh) | 2009-09-24 | 2014-10-29 | 国家健康与医学研究院 | Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍 |
| WO2011109112A2 (en) | 2010-03-05 | 2011-09-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of detecting tau protein and tau fragments in serum |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| AU2013205313B2 (en) | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2701743A4 (en) | 2011-04-27 | 2015-08-19 | Univ Northwestern | FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
| US20120321594A1 (en) | 2011-05-06 | 2012-12-20 | New York University | Methods of controlling axon or dendrite development of neuronal cells |
| JP6457263B2 (ja) | 2011-05-20 | 2019-01-23 | オリゴメリックス インコーポレイテッド | タウプロテアーゼ組成物および使用方法 |
| GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US9926353B2 (en) | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| ME03008B (me) | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| KR101981351B1 (ko) | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| US20140294724A1 (en) | 2011-10-24 | 2014-10-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| JP2015502340A (ja) * | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| US20130251731A1 (en) * | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
| PL2857039T3 (pl) | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| SG10201708959WA (en) * | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| EP2887955B1 (en) | 2012-08-21 | 2020-08-19 | Institute for Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
| EP2906596B1 (en) | 2012-10-12 | 2023-12-27 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| US9910048B2 (en) | 2012-12-03 | 2018-03-06 | Washington University | Method for detection of aggregates in biological samples |
| US8921150B2 (en) | 2012-12-06 | 2014-12-30 | Taiwan Semiconductor Manufacturing Co., Ltd. | Process to achieve contact protrusion for single damascene via |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2014159244A2 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
| EP2968548B1 (en) | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
-
2015
- 2015-06-25 TW TW108111964A patent/TWI734975B/zh not_active IP Right Cessation
- 2015-06-25 TW TW104120634A patent/TWI664190B/zh not_active IP Right Cessation
- 2015-06-25 TW TW109146224A patent/TW202136296A/zh unknown
- 2015-06-26 JP JP2017520755A patent/JP6626892B2/ja active Active
- 2015-06-26 RU RU2017102514A patent/RU2743152C2/ru active
- 2015-06-26 MA MA040229A patent/MA40229A/fr unknown
- 2015-06-26 PE PE2016002780A patent/PE20170665A1/es unknown
- 2015-06-26 CR CR20170026A patent/CR20170026A/es unknown
- 2015-06-26 MX MX2017000205A patent/MX384790B/es unknown
- 2015-06-26 CA CA3094638A patent/CA3094638A1/en not_active Abandoned
- 2015-06-26 SG SG11201610862VA patent/SG11201610862VA/en unknown
- 2015-06-26 CA CA2953809A patent/CA2953809C/en active Active
- 2015-06-26 BR BR112016030686A patent/BR112016030686A2/pt not_active Application Discontinuation
- 2015-06-26 KR KR1020167036625A patent/KR102431596B1/ko active Active
- 2015-06-26 UA UAA201700707A patent/UA122771C2/uk unknown
- 2015-06-26 ES ES15810923T patent/ES2959528T3/es active Active
- 2015-06-26 CN CN201580046263.9A patent/CN106659759B/zh active Active
- 2015-06-26 SG SG10201914067XA patent/SG10201914067XA/en unknown
- 2015-06-26 UY UY0001036194A patent/UY36194A/es not_active Application Discontinuation
- 2015-06-26 AU AU2015279643A patent/AU2015279643B2/en active Active
- 2015-06-26 WO PCT/US2015/038002 patent/WO2015200806A2/en not_active Ceased
- 2015-06-26 EP EP15810923.1A patent/EP3182987B1/en active Active
- 2015-06-26 MY MYPI2016704772A patent/MY184540A/en unknown
- 2015-06-26 NZ NZ727919A patent/NZ727919A/en not_active IP Right Cessation
-
2016
- 2016-09-06 US US15/257,086 patent/US9957317B2/en active Active
- 2016-12-22 IL IL249734A patent/IL249734B/en active IP Right Grant
- 2016-12-22 ZA ZA2016/08875A patent/ZA201608875B/en unknown
- 2016-12-23 PH PH12016502608A patent/PH12016502608A1/en unknown
- 2016-12-26 DO DO2016000335A patent/DOP2016000335A/es unknown
- 2016-12-27 CL CL2016003346A patent/CL2016003346A1/es unknown
-
2017
- 2017-01-04 MX MX2021008888A patent/MX2021008888A/es unknown
- 2017-01-27 EC ECIEPI20175649A patent/ECSP17005649A/es unknown
-
2018
- 2018-03-23 US US15/934,413 patent/US20180371066A1/en not_active Abandoned
-
2019
- 2019-12-02 JP JP2019217837A patent/JP2020054356A/ja active Pending
-
2020
- 2020-03-27 IL IL273656A patent/IL273656B/en unknown
-
2021
- 2021-01-04 PH PH12021550023A patent/PH12021550023A1/en unknown
- 2021-07-08 AU AU2021204800A patent/AU2021204800A1/en not_active Abandoned
- 2021-12-02 IL IL288649A patent/IL288649A/en unknown
- 2021-12-02 JP JP2021195942A patent/JP2022050392A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| ECSP17008984A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| BR112016005303A2 (pt) | anticorpos anti-b7-h1 para tratamento de tumores | |
| MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
| AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
| MX386543B (es) | Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo. | |
| EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. | |
| AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| HK1233163A1 (en) | Humanized anti-tau antibodies | |
| AR102320A1 (es) | Anticuerpos anti-tau humanizados | |
| AR101185A1 (es) | Anticuerpos anti-factor v o factor v activado | |
| AR110569A1 (es) | ANTICUERPOS MONOCLONALES ANTI-a-SINUCLEÍNA PARA PREVENIR LA AGREGACIÓN DE TAU | |
| EA202092279A1 (ru) | Антитела к mica и/или micb и их применение | |
| AR101565A1 (es) | Anticuerpos anti tigit | |
| EA202090201A2 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток |